Bench to Bedside Targeting of FLT3 in Acute Leukemia
- 1 July 2010
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Drug Targets
- Vol. 11 (7), 781-789
- https://doi.org/10.2174/138945010791320782
Abstract
Abstract: FMS-Like-Tyrosine kinase-3 (FLT3) mutations are found in about 30% of cases of acute myeloid leukemia and confer an increased relapse rate and reduced overall survival. Targeting this tyrosine kinase by direction inhibition is the focus of both preclinical and clinical research in AML. Several molecules in clinical development inhibit FLT3, but thus far clinical responses have been limited. Correlative studies from monotherapy trials have established that responses require sustained, effective FLT3 inhibition in vivo. Studies combining FLT3 inhibitors with chemotherapy have demonstrated increased remission rates to date but have yet to produce a survival advantage. Currently the only approved FLT3 inhibitor available for off-label use is sorafenib, which clearly has clinical activity but does not commonly lead to a complete response. Several FLT3 inhibitors are currently being tested as single agents and in combination with chemotherapy, and it seems likely that a clinically useful drug will eventually emerge.Keywords
This publication has 99 references indexed in Scilit:
- Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid TumorsThe Oncologist, 2007
- AS602868, a dual inhibitor of IKK2 and FLT3 to target AML cellsLeukemia, 2007
- Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamicsBlood, 2006
- A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapyBlood, 2006
- Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitorsBlood, 2006
- Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathwaysBlood, 2006
- Phase II Study of Sorafenib in Patients With Advanced Hepatocellular CarcinomaJournal of Clinical Oncology, 2006
- Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITDBlood, 2006
- FLT3: ITDoes matter in leukemiaLeukemia, 2003
- Structure of the protein tyrosine kinase domain of C-terminal Src kinase (CSK) in complex with staurosporineJournal of Molecular Biology, 1999